News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ERYtech Pharma Signs an Agreement With M. D. Anderson Cancer Center to Develop a Companion Test for GRASPA(R) in Solid Tumors


2/16/2010 7:10:50 AM

Bookmark and Share

LYON, France & PHILADELPHIA, pa.--(BUSINESS WIRE)--ERYtech Pharma, a specialty pharma company located in France and in USA (Philadelphia), is pleased to announce a collaborative research agreement in the field of personalized medicine focusing on ERYtech’s flagship product, GRASPA®, which consists of red blood cell-encapsulated L-asparaginase (L-ASP).

Pr. John Weinstein, Chair of the Department of Bioinformatics and Computational Biology at M.D. Anderson Cancer Center (Houston, TX) and principal investigator of the project, states “L-ASP is a standard component of leukemia chemotherapy regimens, but it’s not used yet against solid tumors due to erratic activity. We’ve identified a candidate biomarker, asparagine synthetase (ASNS) that may predict L-ASP activity against solid tumors.”

Dr. Philip Lorenzi, who leads the project, adds “We’re very interested in studying GRASPA® because of its reported reduction of L-asparaginase side effects.”

ERYtech Pharma’s Co-Founder and CEO, Dr. Yann Godfrin says “Collaboration with M. D. Anderson Cancer Center provides us the opportunity to develop a clinically-compatible biomarker assay and to rationally prescribe GRASPA® to patients who are most likely to respond. Toward that end, the M. D. Anderson’s researchers will analyze patient samples from ERYtech’s clinical trials.”

About ERYtech Pharma

ERYtech Pharma is a specialty pharma company developing innovative therapeutic solutions based on its proprietary technology and expertise in the physiological properties of erythrocytes. The company addresses serious pathologies, orphan indications or sub-populations of patients, particularly in the fields of haematology, cancer and metabolic diseases.

www.erytech.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES